Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease. We focus on preclinical drug development, target validation, and IND-enabling studies. Alectos develops innovative new strategies to address medical conditions for which there are no effective treatments.

Our most advanced program is directed towards development of first-in-class agents that modulate O-GlcNAcase (OGA) as a disease-modifying therapy for neurodegenerative disease, including progressive supranuclear palsy, Alzheimer’s disease, and Parkinson’s disease. As part of its pipeline, Alectos is also developing selective inhibitors of non-lysosomal glucosylceramidase (GBA2) as a strategy to address lysosomal dysfunction in neurodegenerative disease. Our GBA2 program is directed toward Niemann-Pick type C disease, Parkinson’s disease, and other neurological disorders where lysosomal dysfunction plays a role.